Latest Articles
Missing the mark: Census 2026 ‘fails to ask’ Australia’s big questions - Herald Sun
Missing the mark: Census 2026 ‘fails to ask’ Australia’s big questions Herald Sun
Published: Aug. 11, 2026, 8:32 p.m.
New Norwood business promises women ‘more than medication’ - InDaily South Australia
New Norwood business promises women ‘more than medication’ InDaily South Australia
Published: Aug. 10, 2026, 12:29 a.m.
How a Mislabeled Biopsy Can Lead to a Cancer Misdiagnosis, As Shown By a Georgia Woman's Lawsuit - inkl
How a Mislabeled Biopsy Can Lead to a Cancer Misdiagnosis, As Shown By a Georgia Woman's Lawsuit inkl
Published: Aug. 8, 2026, 1:20 a.m.
Romanda Hombir is heading to represent SA at Miss World – ‘I am so incredibly elated’ - News24
Romanda Hombir is heading to represent SA at Miss World – ‘I am so incredibly elated’ News24
Published: Aug. 7, 2026, 1:03 p.m.
Ga. woman files lawsuit after cancer misdiagnosis leads to unnecessary hysterectomy - WRDW
Ga. woman files lawsuit after cancer misdiagnosis leads to unnecessary hysterectomy WRDW
Published: Aug. 6, 2026, 1:05 a.m.
Woman files lawsuit after alleged cancer misdiagnosis leads to unnecessary hysterectomy - WTHI-TV
Woman files lawsuit after alleged cancer misdiagnosis leads to unnecessary hysterectomy WTHI-TV
Published: Aug. 4, 2026, 9:11 p.m.
'Medical misogyny': thousands of women face losing life-changing pain drug - The Advocate | Burnie, TAS
'Medical misogyny': thousands of women face losing life-changing pain drug The Advocate | Burnie, TAS
Published: Aug. 4, 2026, 6:31 p.m.
Laura Mbatha shares update on Natalie Githinji’s condition after hospital admission - K24 Digital
Laura Mbatha shares update on Natalie Githinji’s condition after hospital admission K24 Digital
Published: Aug. 4, 2026, 4:09 a.m.
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com - Investing.com UK
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com Investing.com UK
Published: Aug. 1, 2026, 6:38 a.m.
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial The Clinical Trial Vanguard
Published: Aug. 1, 2026, 6:33 a.m.
Link copied to clipboard!